{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adjustment+Disorder&page=2",
    "query": {
      "condition": "Adjustment Disorder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adjustment+Disorder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T17:43:49.150Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000422",
      "title": "Tailored Treatments of Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Cognitive-behavioral psychotherapy and physical exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 65 Years · Female only"
      },
      "enrollment_count": 312,
      "start_date": "1998-07",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000422"
    },
    {
      "nct_id": "NCT00693212",
      "title": "Further Studies of Attention Deficit Disorder - Residual Type (RT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 116,
      "start_date": "1986-02",
      "completion_date": "1994-11",
      "has_results": false,
      "last_update_posted_date": "2008-06-06",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693212"
    },
    {
      "nct_id": "NCT00323427",
      "title": "Clinical Trial of the \"Living Well With Hearing Loss Workshop\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hearing Loss",
        "Stress"
      ],
      "interventions": [
        {
          "name": "The Living Well with Hearing Loss Workshop",
          "type": "BEHAVIORAL"
        },
        {
          "name": "hearing aid services",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 135,
      "start_date": "2007-05",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-03-06",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 2,
      "location_summary": "Bay Pines, Florida • Portland, Oregon",
      "locations": [
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323427"
    },
    {
      "nct_id": "NCT01445535",
      "title": "Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Peripheral Lymphoma",
        "Gamma Delta Hepatosplenic T-Cell Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma",
        "NK T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Siplizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 15,
      "start_date": "2009-01-13",
      "completion_date": "2020-10-22",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445535"
    },
    {
      "nct_id": "NCT07263035",
      "title": "Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure",
        "Heart Failure - NYHA II - IV",
        "Heart Failure Acute",
        "Acute Heart Failure (AHF)"
      ],
      "interventions": [
        {
          "name": "Furosemide intravenous solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakeland Regional Health Systems, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2026-04-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Lakeland, Florida",
      "locations": [
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07263035"
    },
    {
      "nct_id": "NCT05838248",
      "title": "Complex and Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Appendicitis"
      ],
      "interventions": [
        {
          "name": "antibiotic duration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2023-01-24",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838248"
    },
    {
      "nct_id": "NCT00345618",
      "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Embolism",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Idrabiotaparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for idrabiotaparinux sodium)",
          "type": "DRUG"
        },
        {
          "name": "Avidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for warfarin)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3202,
      "start_date": "2006-06",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345618"
    },
    {
      "nct_id": "NCT04404192",
      "title": "PH94B in the Treatment of Adjustment Disorder With Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adjustment Disorder With Anxious Mood"
      ],
      "interventions": [
        {
          "name": "PH94B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VistaGen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-10-12",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 2,
      "location_summary": "Watertown, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Watertown",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404192"
    },
    {
      "nct_id": "NCT00069238",
      "title": "Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, T-Cell",
        "Lymphoma, Extranodal NK-T-Cell"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab (Campath)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EPOCH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2003-09-19",
      "completion_date": "2021-03-17",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069238"
    },
    {
      "nct_id": "NCT00361504",
      "title": "A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Hip",
        "Osteoarthritis, Knee",
        "Lower Back Pain",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone CR",
          "type": "DRUG"
        },
        {
          "name": "Tapentadol (CG5503) ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1123,
      "start_date": "2006-11",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-06-10T17:43:49.150Z",
      "location_count": 40,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cudahy",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00361504"
    }
  ]
}